Risk management decisions in women with BRCA1 and BRCA2 mutations

Rosemary Morgan, Audrey Brown, Kelly Hamman, Jone Sampson, Arpana Naik, Kristen Massimino

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Pathogenic mutations and variants of uncertain significance (VUS) occur in BRCA1/2 genes. Methods: Records of women with a pathogenic mutation or VUS in BRCA1/2 treated between 2008 and 2017 were reviewed. Results: One hundred and ten women were included. Mean age was 47. A pathogenic mutation or a VUS in BRCA1/2 was detected in 85 (77%) and 25 (23%) patients, respectively. The rate of risk reducing mastectomy (RRM) was 50% in women with a pathogenic mutation and 30% in women with a VUS (P = 0.232). Among women with breast cancer, 65% with a pathogenic mutation and 40% with a VUS underwent RRM. Over 50% of women with a pathogenic mutation in BRCA1/2 chose surveillance over operation. Discussion: There was no statistical difference in the rate of RRM among women with a pathogenic mutation or a VUS in BRCA1/2 in our population. The majority of high risk women in our study chose to forgo RRM for breast cancer screening.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Risk Management
Mutation
Mastectomy
Breast Neoplasms
BRCA1 Gene
Early Detection of Cancer
Population

Keywords

  • BRCA
  • Breast cancer
  • Genetic testing
  • Variants of uncertain significance

ASJC Scopus subject areas

  • Surgery

Cite this

Risk management decisions in women with BRCA1 and BRCA2 mutations. / Morgan, Rosemary; Brown, Audrey; Hamman, Kelly; Sampson, Jone; Naik, Arpana; Massimino, Kristen.

In: American Journal of Surgery, 01.01.2018.

Research output: Contribution to journalArticle

Morgan, Rosemary ; Brown, Audrey ; Hamman, Kelly ; Sampson, Jone ; Naik, Arpana ; Massimino, Kristen. / Risk management decisions in women with BRCA1 and BRCA2 mutations. In: American Journal of Surgery. 2018.
@article{635a80bef70d4c7e85282cf5ddad17eb,
title = "Risk management decisions in women with BRCA1 and BRCA2 mutations",
abstract = "Introduction: Pathogenic mutations and variants of uncertain significance (VUS) occur in BRCA1/2 genes. Methods: Records of women with a pathogenic mutation or VUS in BRCA1/2 treated between 2008 and 2017 were reviewed. Results: One hundred and ten women were included. Mean age was 47. A pathogenic mutation or a VUS in BRCA1/2 was detected in 85 (77{\%}) and 25 (23{\%}) patients, respectively. The rate of risk reducing mastectomy (RRM) was 50{\%} in women with a pathogenic mutation and 30{\%} in women with a VUS (P = 0.232). Among women with breast cancer, 65{\%} with a pathogenic mutation and 40{\%} with a VUS underwent RRM. Over 50{\%} of women with a pathogenic mutation in BRCA1/2 chose surveillance over operation. Discussion: There was no statistical difference in the rate of RRM among women with a pathogenic mutation or a VUS in BRCA1/2 in our population. The majority of high risk women in our study chose to forgo RRM for breast cancer screening.",
keywords = "BRCA, Breast cancer, Genetic testing, Variants of uncertain significance",
author = "Rosemary Morgan and Audrey Brown and Kelly Hamman and Jone Sampson and Arpana Naik and Kristen Massimino",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.amjsurg.2018.02.010",
language = "English (US)",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Risk management decisions in women with BRCA1 and BRCA2 mutations

AU - Morgan, Rosemary

AU - Brown, Audrey

AU - Hamman, Kelly

AU - Sampson, Jone

AU - Naik, Arpana

AU - Massimino, Kristen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Pathogenic mutations and variants of uncertain significance (VUS) occur in BRCA1/2 genes. Methods: Records of women with a pathogenic mutation or VUS in BRCA1/2 treated between 2008 and 2017 were reviewed. Results: One hundred and ten women were included. Mean age was 47. A pathogenic mutation or a VUS in BRCA1/2 was detected in 85 (77%) and 25 (23%) patients, respectively. The rate of risk reducing mastectomy (RRM) was 50% in women with a pathogenic mutation and 30% in women with a VUS (P = 0.232). Among women with breast cancer, 65% with a pathogenic mutation and 40% with a VUS underwent RRM. Over 50% of women with a pathogenic mutation in BRCA1/2 chose surveillance over operation. Discussion: There was no statistical difference in the rate of RRM among women with a pathogenic mutation or a VUS in BRCA1/2 in our population. The majority of high risk women in our study chose to forgo RRM for breast cancer screening.

AB - Introduction: Pathogenic mutations and variants of uncertain significance (VUS) occur in BRCA1/2 genes. Methods: Records of women with a pathogenic mutation or VUS in BRCA1/2 treated between 2008 and 2017 were reviewed. Results: One hundred and ten women were included. Mean age was 47. A pathogenic mutation or a VUS in BRCA1/2 was detected in 85 (77%) and 25 (23%) patients, respectively. The rate of risk reducing mastectomy (RRM) was 50% in women with a pathogenic mutation and 30% in women with a VUS (P = 0.232). Among women with breast cancer, 65% with a pathogenic mutation and 40% with a VUS underwent RRM. Over 50% of women with a pathogenic mutation in BRCA1/2 chose surveillance over operation. Discussion: There was no statistical difference in the rate of RRM among women with a pathogenic mutation or a VUS in BRCA1/2 in our population. The majority of high risk women in our study chose to forgo RRM for breast cancer screening.

KW - BRCA

KW - Breast cancer

KW - Genetic testing

KW - Variants of uncertain significance

UR - http://www.scopus.com/inward/record.url?scp=85042591276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042591276&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2018.02.010

DO - 10.1016/j.amjsurg.2018.02.010

M3 - Article

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

ER -